Ningkang Xiaowei Biopharmaceutical

Ningkang Xiaowei Biopharmaceutical is a Chinese biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company specializes in developing oral agonists for G-protein coupled receptors (GPCRs), specifically targeting the GLP-1, GIP, and Glucagon pathways. Their lead research efforts are directed toward creating next-generation treatments for type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). By leveraging expertise in medicinal chemistry, Ningkang Xiaowei aims to provide effective oral alternatives to injectable peptide-based metabolic therapies.